We are monitoring the impact of COVID-19 & Recession alarm on APAC Angina Pectoris Drugs Market Get in touch with us for detailed analysis Know More

Know More

Share on

Asia Pacific Angina Pectoris Drugs Market Research Report – Segmented By Therapeutic Class & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 8025
Pages: 145

APAC Angina Pectoris Drugs Market Size (2022 to 2027)

The size of the Asia Pacific angina pectoris drugs market is forecasted to be growing at a healthy rate of 5.07% between 2022 to 2027.

The growing burden of lifestyle diseases in the aging population directly affects the socio-economic aspects of nations, requiring immediate action to limit and control them. As a result, the APAC angina pectoris drugs market is primarily driven by the increasing prevalence of lifestyle-related diseases like obesity, cardiovascular disease, diabetes, hypertension, etc. It is estimated that over 15.8 million people suffer from angina pectoris each year, and up to 600,000 new cases are diagnosed each year. The prevalence of angina increases dramatically with age in both sexes, ranging from 2.5% to 5.2% in men aged 45 to 54 and from 10.3% to 20.2% in men 65 to 74 years old and between 0.15% and 1.2% of women aged 45- 54 and 10.9%. 15.3% among women aged 65 to 74. The ease of availability of therapeutic drugs for angina pectoris, the development of new drugs, and the increased awareness of various cardiovascular disorders are anticipated to drive this market growth during the forecast period.

The annual risk of associated non-fatal myocardial infarction (MI) and death is reported at 3.1% and 1.1-2.1%, respectively. Technological advances in personalized cardiovascular medicine and improvements in innovative drug delivery systems are other driving forces. Chronic stable angina affects 3-5% of the population in APAC countries, with an estimated annual risk of death and non-fatal myocardial infarction (MI) of 1-2%. The continuous development of new diagnostic tests and therapies for the treatment of angina is anticipated to provide potential growth opportunities for market growth.

However, factors such as low healthcare expenditure per capita and high cost of surgeries such as coronary artery bypass grafting are anticipated to limit the market growth during the forecast period. Moreover, a lack of reimbursement programs to cover the drug costs may challenge the market in specific APAC regional markets during the forecast period.

This research report on the APAC angina pectoris drugs market has been segmented & sub-segmented into the following categories:

By Therapeutic Class:

  • Beta-Blockers     
  • Calcium Antagonists      
  • Anticoagulants    
  • Anti-Platelets     
  • Others    

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The Chinese regional market is anticipated to experience significant growth during the forecast period in this region. China offers an excellent opportunity for market expansion due to the easy availability of drugs, the ongoing health reform for Healthy China 2020, and the 12th Five-Year Plan support measures targeting biotechnology as a key development sector. In addition, the presence of a large target population and high unmet clinical needs are some of the factors that are anticipated to drive growth in this region. The CVD death rate in rural Chinese areas exceeded that of urban areas, and in 2017 the rate was 319.23 per 100,000 population in rural areas and 269.51 per 100 000 inhabitants in urban areas. In early 2010, the incidence was reported at 72.4% million non-smokers in China were exposed to second-hand smoke; this also hikes the prevalence rates in China.

The market for angina pectoris drugs in India is also anticipated to grow steadily due to the increasing prevalence of angina pectoris, high awareness of CVD, large patient base, and improved health infrastructure. However, the prevalence of angina decreased from 27.82% to 11.24% over five years in India, attributed to improving healthcare infrastructure and social reforms.

Other Asia-Pacific regions like Australia, Japan, South Korea, and Taiwan are anticipated to grow at a good rate due to a large target population, improving pharmaceutical companies, and significant unmet clinical needs.


Some of the major companies dominating the market by their products and services include Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd., and Baxter Healthcare Corporation.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutic class                     

                                5.1.1 Introduction           

                                5.1.2 Beta blockers         

                                5.1.3 Calcium anatagonists          

                                5.1.4 Anticoagulants      

                                5.1.5 Anti platelets         

                                5.1.6 Others      

                                5.1.7  Y-o-Y Growth Analysis, By therapeutic class            

                                5.1.8  Market Attractiveness Analysis, By therapeutic class          

                                5.1.9 Market Share Analysis, By therapeutic class             

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                       By Geographical Area

                                       By therapeutic class

                                6.1.4  Market Attractiveness Analysis     

                                       By Geographical Area

                                       By therapeutic class

                                6.1.5  Market Share Analysis      

                                       By Geographical Area

                                       By therapeutic class

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Anthera Pharmaceuticals                     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Cardium Therapeutics                            

                8.3 Sanofi                           

                8.4 Bayer HealthCare                     

                8.5 Cardeus Pharmaceuticals                     

                8.6 Ark Therapeutics Group plc                 

                8.7 Torrent Pharmaceuticals Limited                       

                8.8 Circ Pharma Limited                

                8.9 Viromed Co. Ltd.                      

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         


                a) List of Tables                

                b) List of Figures                              

  1. Asia Pacific Angina Pectoris drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  2. Asia Pacific Beta blockers Market, By Region, From 2022 - 2027 (USD Billion)
  3. Asia Pacific Calcium antagonists Market, By Region, From 2022 - 2027 (USD Billion)
  4. Asia Pacific Anti coagulants Market, By Region, From 2022 - 2027 (USD Billion)
  5. Asia Pacific Anti platelets Market, By Region, From 2022 - 2027 (USD Billion)
  6. Asia Pacific Others Market, By Region, From 2022 - 2027 (USD Billion)
  7. Japan Angina Pectoris drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  8. China Angina Pectoris drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  9. India Angina Pectoris drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  10. Australia Angina Pectoris drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  11. South Korea Angina Pectoris drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports




pdf excel


pdf excel powerbi




What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.

Talk to our analyst and get customised report done according to your research needs


Check if you can avail any discount. Submit your details and our team will get back to you.


Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?

Find it too expensive?

Click for Request Sample